Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression
Introduction. The question of the advisability of neoadjuvant chemotherapy (NACT) in patients with oral cavity squamous cell carcinoma is still controversial.Aim. To identify a group of patients at high risk of progression and death from the oral cavity squamous cell carcinoma, with resectable stage...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-07-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/1070 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240818915737600 |
|---|---|
| author | S. I. Kutukova Yu. V. Ivaskova N. P. Beliak G. A. Raskin A. A. Varankina A. I. Yaremenko A. Ya. Razumova A. O. Cheremnykh M. F. Manna R. V. Orlova |
| author_facet | S. I. Kutukova Yu. V. Ivaskova N. P. Beliak G. A. Raskin A. A. Varankina A. I. Yaremenko A. Ya. Razumova A. O. Cheremnykh M. F. Manna R. V. Orlova |
| author_sort | S. I. Kutukova |
| collection | DOAJ |
| description | Introduction. The question of the advisability of neoadjuvant chemotherapy (NACT) in patients with oral cavity squamous cell carcinoma is still controversial.Aim. To identify a group of patients at high risk of progression and death from the oral cavity squamous cell carcinoma, with resectable stages, and to determine the effectiveness of docetaxel and cisplatin (TP) NACT patients with high-risk oral cavity squamous cell carcinoma.Materials and methods. At the 1st stage of our study, we retrospectively analyzed the data of 98 patients and determine that the NACT for patients with oral cavity squamous cell carcinoma, with 3 or more factors of an unfavorable prognosis (peripheral blood parameters indicating the presence of systemic inflammation, reduced level of infiltration of tumor structures by CD8‑tumor infiltrating lymphocytes and low expression of programmed death-ligand 1 (PD-L1) on tumor and immune cells) significantly reduces the risk of death and disease progression: hazard ratio 0.33; 95 % confidence interval 0.13–0.86; p = 0.0231. In 2nd part of study we assessed the effectiveness of 3 cycles of NACT with docetaxel + cisplatin in 24 patients with 4 or more unfavorable prognosis factors.Results. Objective response rate after 3 cycles of NACT was 66.7 % (16 / 24): 1 / 24 (4.2 %) patient had complete response, and 15 / 24 (62.5 %) patients had a partial response. NACT allowed achieving disease control rate in a significant majority of patients – 23 / 24 (95.9 %) (p <0.001). The medians of overall survival and progression-free survival weren’t reached at the time of the data cutoff (with a median follow-up of 56.5 months).Conclusion. Our study allows to conclude that it is necessary in real clinical practice to identify patients with oral cavity squamous cell carcinoma with high-risk of progression and death in order to prescribe them NACT before surgery to increase the effectiveness of treatment and reduce the risk of progression and. |
| format | Article |
| id | doaj-art-a2deb67c7e3440538d4383ea1a96c592 |
| institution | Kabale University |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2025-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-a2deb67c7e3440538d4383ea1a96c5922025-08-20T04:00:26ZrusABV-pressОпухоли головы и шеи2222-14682411-46342025-07-01152435010.17650/2222-1468-2025-15-2-43-50637Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progressionS. I. Kutukova0Yu. V. Ivaskova1N. P. Beliak2G. A. Raskin3A. A. Varankina4A. I. Yaremenko5A. Ya. Razumova6A. O. Cheremnykh7M. F. Manna8R. V. Orlova9Pavlov University, Ministry of Health of Russia; City Clinical Oncological DispensaryPavlov University, Ministry of Health of Russia; City Clinical Oncological DispensaryCity Clinical Oncological Dispensary; Saint Petersburg State UniversitySaint Petersburg State University; Treatment and Diagnostic Center of the International Institute Biological System named after Sergey BerezinCity Clinical Oncological DispensaryPavlov University, Ministry of Health of RussiaPavlov University, Ministry of Health of RussiaPavlov University, Ministry of Health of RussiaPavlov University, Ministry of Health of RussiaCity Clinical Oncological Dispensary; Saint Petersburg State UniversityIntroduction. The question of the advisability of neoadjuvant chemotherapy (NACT) in patients with oral cavity squamous cell carcinoma is still controversial.Aim. To identify a group of patients at high risk of progression and death from the oral cavity squamous cell carcinoma, with resectable stages, and to determine the effectiveness of docetaxel and cisplatin (TP) NACT patients with high-risk oral cavity squamous cell carcinoma.Materials and methods. At the 1st stage of our study, we retrospectively analyzed the data of 98 patients and determine that the NACT for patients with oral cavity squamous cell carcinoma, with 3 or more factors of an unfavorable prognosis (peripheral blood parameters indicating the presence of systemic inflammation, reduced level of infiltration of tumor structures by CD8‑tumor infiltrating lymphocytes and low expression of programmed death-ligand 1 (PD-L1) on tumor and immune cells) significantly reduces the risk of death and disease progression: hazard ratio 0.33; 95 % confidence interval 0.13–0.86; p = 0.0231. In 2nd part of study we assessed the effectiveness of 3 cycles of NACT with docetaxel + cisplatin in 24 patients with 4 or more unfavorable prognosis factors.Results. Objective response rate after 3 cycles of NACT was 66.7 % (16 / 24): 1 / 24 (4.2 %) patient had complete response, and 15 / 24 (62.5 %) patients had a partial response. NACT allowed achieving disease control rate in a significant majority of patients – 23 / 24 (95.9 %) (p <0.001). The medians of overall survival and progression-free survival weren’t reached at the time of the data cutoff (with a median follow-up of 56.5 months).Conclusion. Our study allows to conclude that it is necessary in real clinical practice to identify patients with oral cavity squamous cell carcinoma with high-risk of progression and death in order to prescribe them NACT before surgery to increase the effectiveness of treatment and reduce the risk of progression and.https://ogsh.abvpress.ru/jour/article/view/1070squamous cell carcinoma of the oral mucosaneoadjuvant chemotherapydocetaxelcisplatinobjective response |
| spellingShingle | S. I. Kutukova Yu. V. Ivaskova N. P. Beliak G. A. Raskin A. A. Varankina A. I. Yaremenko A. Ya. Razumova A. O. Cheremnykh M. F. Manna R. V. Orlova Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression Опухоли головы и шеи squamous cell carcinoma of the oral mucosa neoadjuvant chemotherapy docetaxel cisplatin objective response |
| title | Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression |
| title_full | Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression |
| title_fullStr | Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression |
| title_full_unstemmed | Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression |
| title_short | Efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression |
| title_sort | efficacy of neoadjuvant chemotherapy with docetaxel and cisplatin in patients with squamous cell carcinoma of the oral cavity at high risk of progression |
| topic | squamous cell carcinoma of the oral mucosa neoadjuvant chemotherapy docetaxel cisplatin objective response |
| url | https://ogsh.abvpress.ru/jour/article/view/1070 |
| work_keys_str_mv | AT sikutukova efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT yuvivaskova efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT npbeliak efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT garaskin efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT aavarankina efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT aiyaremenko efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT ayarazumova efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT aocheremnykh efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT mfmanna efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression AT rvorlova efficacyofneoadjuvantchemotherapywithdocetaxelandcisplatininpatientswithsquamouscellcarcinomaoftheoralcavityathighriskofprogression |